Sprott »

Gain Therapeutics shares owned by Sprott

Quarter-by-quarter ownership of Gain Therapeutics (GANX) shares owned by Sprott from 13F filings

Historical chart of Sprott investment in Gain Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Gain Therapeutics held by Sprott consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Gain Therapeutics by Sprott

Quarter filed Position value Share count Share price at filing
2025-03-31 $27k 14k 1.91
2024-12-31 $30k 14k 2.16

More positions owned by Sprott

Coeur Mng Com New (CDE)
Agnico (AEM)
Sprott Com New (SII)
Wheaton Precious Metals Corp (WPM)
Sprott Focus Tr (FUND)
Spdr S&p 500 Etf Tr Put Put Option
Equinox Gold Corp equities (EQX)
Or Royalties Com Shs (OR)
Vizsla Silver Corp Com New (VZLA)
Iamgold Corp (IAG)
Spdr Series Trust Bloomberg 1-3 Mo (BIL)
Sprott Asset Management Physical Gold Tr (PHYS)
Kinross Gold Corp (KGC)
Pan American Silver Corp Can (PAAS)
Ego (EGO)

View all positions for Sprott

Top funds holding Gain Therapeutics

Jones Financial Companies, L.L
DME Capital Management
Vanguard Group
Citadel Advisors
Geode Capital Management
Cambridge Investment Research Advisors
Marshall Wace
UBS Group
Renaissance Technologies
BlackRock
State Street Corporation
Northern Trust
Susquehanna International
Morgan Stanley
Jane Street

View all funds holding Gain Therapeutics